CoreLink Surpasses 5,000 Entasis SI Joint Fusion Implantations With Patented Stackable Guide Wires

CoreLink, LLC, a leading designer and manufacturer of spinal implant systems, today announced the implantation of over 5,000 Entasis® Lateral SI Joint Fusion System compression screws to fuse the sacroiliac joint. View more.

CoreLink also announced the company has been awarded patent number 11,052,229 by the United States Patent and Trademark Office (USPTO). The patent, titled, “Devices and methods for guidewire extension in spinal surgery,” expands the company’s intellectual property portfolio. These unique stackable guide wires are designed to give surgeons streamlined instruments and constant proximal control during every step of these lateral SI joint fusion procedures.

With the spine market expected to increase 5 percent this year1 and sacroiliac joint fusion growing up to 14.7 percent2, SI joint fusion continues to be an exciting new area of spine surgery. Lower back pain is one of the most common reasons for a physician visit and those experiencing pain attributable to the SI joint range from 15 to 30 percent3.

Entasis is designed for minimally invasive SI joint fusion procedures. The system provides an array of joint stabilizing compression screw options in three diameters and nine length options, enabling surgeons to precisely fit varying patient anatomies. The screws feature circumferential fenestrations that self-harvest bone graft while compressing the joint. Dual leads threads ease insertion and easy-out threaded removal tools are available, if needed. These innovative features and stackable guide wire have led to the Entasis system being recognized as a top 10 sacroiliac joint fusion system by SPINEMarketGroup. A full suite of resources to assist in surgeon training, patient education, and patient workup is also available.

“CoreLink is proud to be a leader in the SI fusion market as a result of our strong product offering and vast training resources,” said Jay Bartling, CEO, CoreLink. “Every step of our process, from design to manufacturing, keeps surgeon ease of use and patient outcomes top of mind. This is evident in our SI joint fusion systems with patented technology, unique compression screw design, and comprehensive offerings.”

CoreLink will be exhibiting at the North American Spine Society’s annual meeting in Boston, September 29 through October 2, booth #3221, where a full display of surgical systems will be featured, including Entasis.


References

1.

The Spine Market Group. (2021). What is the Spine Market First Estimate for 2021. Retrieved from https://thespinemarketgroup.com/which-is-the-spine-market-first-estimate-for-2021.

2.

360 Research Reports. (2020). Global MIS Sacroiliac Joint Fusion Sales Market Report 2020. Retrieved from https://www.360researchreports.com/global-mis-sacroiliac-joint-fusion-sales-market-16695557.

3.

Martin, C. T., Haase, L., Lender, P. A., & Polly, D. W. (2020). Minimally Invasive Sacroiliac Joint Fusion: The Current Evidence. International journal of spine surgery, 14(Suppl 1), 20–29. https://doi.org/10.14444/6072

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.